Company launches product targeting dry eye, MGD
April 20, 2021
ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
All News
Johnson & Johnson earns FDA clearance, CE mark for next-gen phaco machine
April 21, 2021
Johnson & Johnson Vision announced today that the FDA has granted 510(k) clearance and CE mark for its VERTIAST Vision System, a next-generation phacoemulsification innovation.
Adjusting ophthalmology practice to a pandemic
April 19, 2021
Find out how one eye care practice has found success in adapting their services to ensure staff/patient safety throughout the pandemic.
Artificial retina engineered from ancient protein now in space
April 14, 2021
The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.
Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD
April 13, 2021
Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.
ARVO sets stage for virtual event
April 12, 2021
‘Revolutionary Eye and Vision Research’ theme of annual meeting.
CDC notes that surface COVID-19 transmission is rare
April 12, 2021
In an update, the CDC noted that the chances of an individual contracting COVID-19 from surface transmission is low.
Global research initiative formed to study and develop new treatments for glaucoma
April 12, 2021
Santen, Massachusetts Eye and Ear, Ulster University researchers will focus on ways to preserve vision by slowing, reversing, or preventing the damage.
Phase 2 clinical trial kicks off for diabetic retinopathy drug candidate
April 09, 2021
Ocuphire Pharma’s ZETA-1 trial will investigate the potential of APX3330 to offer an oral treatment for diabetic retinopathy.
Hearing and vision loss may pose high risk for dementia
April 08, 2021
A diminishment of both hearing and vision is linked to an increased risk for dementia and mental decline, according to a new study.